Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Inspira Technologies Oxy BHN Ltd (IINN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: IINN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -9.47% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 24.42M USD | Price to earnings Ratio - | 1Y Target Price 13 |
Price to earnings Ratio - | 1Y Target Price 13 | ||
Volume (30-day avg) 345435 | Beta 2.09 | 52 Weeks Range 0.65 - 2.45 | Updated Date 03/30/2025 |
52 Weeks Range 0.65 - 2.45 | Updated Date 03/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.78 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -59.53% | Return on Equity (TTM) -116.54% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 12450823 | Price to Sales(TTM) - |
Enterprise Value 12450823 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.15 | Shares Outstanding 18503500 | Shares Floating 10135177 |
Shares Outstanding 18503500 | Shares Floating 10135177 | ||
Percent Insiders 8.88 | Percent Institutions 0.85 |
Analyst Ratings
Rating 5 | Target Price 9.41 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Inspira Technologies Oxy BHN Ltd
Company Overview
History and Background
Inspira Technologies Oxy BHN Ltd. was founded to develop breakthrough respiratory support technology. It focuses on solutions for critical care and aims to reduce the need for invasive mechanical ventilation. Specific founding year and early milestones details are not readily available publicly.
Core Business Areas
- Respiratory Support Systems: Development and commercialization of advanced respiratory support technology including the ART device.
Leadership and Structure
The company has a board of directors and a management team led by the CEO. Publicly available detailed organizational structure is limited.
Top Products and Market Share
Key Offerings
- ART (Augmented Respiration Technology) System: ART is a minimally invasive respiratory support system designed to prevent the need for invasive mechanical ventilation. Market share is nascent, targeting the acute respiratory distress syndrome (ARDS) market. Competitors include traditional mechanical ventilation providers (e.g., Medtronic, Getinge) and non-invasive ventilation equipment (e.g., ResMed).
Market Dynamics
Industry Overview
The respiratory care market is driven by aging populations, increasing prevalence of respiratory diseases, and technological advancements in ventilation and oxygenation. The COVID-19 pandemic highlighted the critical need for advanced respiratory support technologies.
Positioning
Inspira is positioning itself as an innovator in respiratory support, aiming to disrupt the market with its ART technology. Its competitive advantage lies in the potential to reduce the need for invasive mechanical ventilation and its associated complications.
Total Addressable Market (TAM)
The TAM for respiratory support devices is estimated to be several billion USD annually. Inspira's ART system targets a segment of this market, focused on patients at risk of respiratory failure, placing it in a high-growth potential space.
Upturn SWOT Analysis
Strengths
- Innovative ART technology
- Potential to reduce invasive ventilation
- Focus on unmet clinical needs
Weaknesses
- Limited commercial presence
- Reliance on regulatory approvals
- Dependence on funding
Opportunities
- Expanding market for respiratory support devices
- Partnerships with hospitals and healthcare providers
- Geographic expansion
Threats
- Competition from established medical device companies
- Regulatory hurdles
- Reimbursement challenges
Competitors and Market Share
Key Competitors
- MDT
- GE
- RMD
Competitive Landscape
Inspira faces intense competition from established medical device companies with extensive resources and market access. Inspira's advantage lies in its potentially disruptive technology, while its disadvantage is its limited commercial infrastructure.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by preclinical and clinical development milestones.
Future Projections: Future growth is contingent upon successful clinical trials, regulatory approvals, and commercialization of the ART system. Analyst estimates are not widely available due to the company's early stage.
Recent Initiatives: Recent initiatives focus on clinical trials, regulatory submissions (e.g., FDA clearance), and establishing partnerships.
Summary
Inspira Technologies is a development-stage company with an innovative respiratory support technology. Its success hinges on clinical trial outcomes, regulatory approvals, and commercialization capabilities. The company faces competition from established players in the medical device industry and relies heavily on securing sufficient funding.
Similar Companies
- MDT
- RMD
- ISRG
Sources and Disclaimers
Data Sources:
- Company website, SEC filings, Industry reports
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be based on independent research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Inspira Technologies Oxy BHN Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-07-14 | Co-Founder, CEO & Director Mr. Dagi Shahar Ben-Noon | ||
Sector Healthcare | Industry Medical Devices | Full time employees 37 | Website https://inspira-technologies.com |
Full time employees 37 | Website https://inspira-technologies.com | ||
Inspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacture, and marketing of proprietary life support technology for the treatment of acute respiratory failure. Its lead product is the INSPIRA augmented respiration technology (Gen 2) device, a life support designed to provide Adaptive Blood Oxygenation that to elevate and stabilize declining oxygen saturation levels. The company has a strategic collaboration with Westchester Medical Center to advance critical patient care with the deployment of Inspira's proprietary INSPIRA ART100 systems. The company was formerly known as Insense Medical Ltd. and changed its name to Inspira Technologies Oxy B.H.N. Ltd. in July 2020. Inspira Technologies Oxy B.H.N. Ltd. was incorporated in 2018 and is headquartered in Ra'anana, Israel.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.